

Information about the Annual General Meeting 2020 and invitation to CEO presentation

The Annual General Meeting will be held on Tuesday, 28 April 2020 at 2:00 pm at the company's head office at Alfred Nobels Allé 150 in Tullinge. Due to the outbreak of the Covid-19 virus and for the safety of Bactiguard shareholders, the company urges all shareholders not to participate personally, but instead take advantage of the opportunity to vote remotely. Prior to the meeting, Bactiguard's CEO will give a speech online with the opportunity for the audience to ask questions.

The registration period for the AGM runs until Wednesday 22 April and the opportunity to vote until 24 April. More information on precautions in connection with Covid-19 and guide to voting can be found on the company's website: <https://www.bactiguard.se/en/for-investors/corporate-governance/general-meetings/annual-general-meeting-2020>

The CEO Cecilia Edström's presentation will be held online before the Annual General Meeting, starting at 1.15 pm Tuesday, April 28, 2020. The webcast, which will be held in English, is open to all investors and there will be the opportunity to ask questions. This webcast replaces the CEO's presentation at the AGM.

To participate in the webcast, please use this link: <https://tv.streamfabriken.com/2020-04-28-bactiguard-pressconference>

For further information, please contact:

Cecila Edström, CEO, phone: +46 8 440 58 80

About Bactiguard

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through license agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our license partner BD, urinary catheters with Bactiguard's coating are market leading in the USA and Japan. Bactiguard's own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections which appear in the urinary tract, the blood stream and the respiratory tract.



Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention.

Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia.

Bactiguard is listed on Nasdaq Stockholm.

Read more about how Bactiguard saves lives at www.bactiguard.com